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HIV DISEASE 
AND SURGERY
Simple observation has made it clear that HIV is now a chronic 
disease. The massive impact of anti-retroviral therapy on life 
expectancy would imply that a recently diagnosed man of 25 years 
could expect to live a further 39 years.(1) 
In this brief review the different aspects of cardiac surgery carried 
out, recognising that some units do vascular surgery as well, are 
discussed. Answers to some questions are clear ; progress made, 
especially with the advent of the double-edged sword of anti-
retroviral  therapy, and changed attitudes, are considered. 
VALVE  SURGERY                                                              
The landmark paper by Frater and colleagues(2) in 1989 showed 
that human immuno-defi ciency virus (HIV+) patients could be 
taken through surgery successfully. Striking features were: all but 
1 of the 10 patients having 11 valve replacements, for infective 
endocarditis (IE) were intravenous drug addicts (IVDA), and, 
further, despite conventional medical therapy, 7 of these still had 
active infective endocarditis (AIE) at surgery (Table 1).  In contrast, 
only 2 of 10 uninfected controls (HIV-) still had evidence of 
sepsis at surgery.  One of the 7 with uncontrolled AIE died peri-
Uncertainties concerning the effects of cardiopulmonary 
bypass, outcome and possibility of operator injury slowed 
progress in cardiac surgery in the HIV-infected patient. 
Severely ill patients, some with AIDS and others probably 
with AIDS, formed the basis of early reports; it was shown 
they could be taken through surgery satisfactorily. Follow-
ing the advent of antiretroviral monotherapy – zidovudine, 
an NRTI – in 1987, and  dual therapy in the early 1990s 
with NRTIs, the addition of protease inhibitors (PI) in 1995, 
although a double-edged sword, led to triple therapy/ 
HAART, (2 NRTIs and a PI) and startling improvement in 
morbidity and mortality in markedly compromised HIV 
patients. Yet, it was only in 2003 when sizeable reports 
carrying ARV usage began to emerge. Intravenous drug ad-
diction causing left-sided valvular heart disease was initially 
responsible for most cases, but there was now an increase in 
coronary artery disease (CAD) in young patients, blamed 
partly on lipid disturbances caused by PI. With an ARV roll-
out in South Africa delayed to 2004, and PIs only used in 
second line therapy in State-administered treatment, the 
increase in coronary artery disease has not been noted. 
The need for surgery in pericardial disease is rare. Paedi-
atric cardiac surgery has been rarely reported, but is locally 
carried out; a new approach to medical management of 
these children should lead to more frequent surgery. Heart 
transplantation lags far behind solid organ transplantation, 
but there are indications that it will be more readily accepted. 
Certain vascular pathologies appear to be peculiar to HIV, 
with the virus itself being able to enter vessel walls with 
evolution of vascular disease. PIs would appear to accelerate 
coronary artery disease, as seen in younger HIV patients, 
who develop abnormal lipid profi les. The approach to cardiac 
surgery in most cardiac teaching units is looked at. Many 
answers have been found, but new issues have also arisen, as 
in relation to ARV’s and CAD. Most importantly, attitudes 
are changing: some would accept selected patients with 
AIDS not receiving ARVs. Very good results have followed 
surgery in patients who have suffered AIDS defi ning 
conditions but are stable on ARVs.  SAHeart 2009; 6:210-221
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hospital clinically well, 1 dying of suspected but unproven AIDS 
at 41/2 months (Table 1). No prognostic markers were used; 
possibly some of these patients actually had AIDS, persistent sepsis 
perhaps being an indicator of immune defi ciency. Frater et al.(3) 
suggested that surgery might not remove infection as it did in 
the HIV negative (HIV-).  This paper raised more questions.
Yee (1991)(4) reported on 3 valve replacements and 3 coronary 
artery bypass grafts (CABG) in patients with AIDS, 3 being in 
extremis at time of emergency surgery.  All survived surgery with a 
“benign” post-operative course. Three valve patients died with 
“fulminant AIDS” within 60 days. Yee questioned “the safety of 
cardiopulmonary bypass (CPB) in HIV-infected patients”.          
Cardiopulmonary bypass (CPB) was well known to cause a defi -
nite but transient depression of the immune system.(5,6)  Frater’s 
and  Yee’s  papers did not answer the question whether the disease 
was worsened by cardiopulmonary bypass, but then theirs were of 
the sickest patients, and most compromised, one might take to 
surgery. Nevertheless, both thought life-saving surgery was 
warranted in these very ill patients. Concern about transmission of 
infection to team members was expressed.(2) 
In 4 reports(7-9,11) of small numbers (Table 2), including  patients 
with AIDS, according to CD4 counts and other markers, al-
though progression to AIDS was seen, no-one was discouraged 
by their results: similar results as in HIV- could be expected,(11) 
TABLE 1:  Ten largest publications:  Cardiovascular surgery in HIV+ patients using cardiopulmonary bypass (period from 1989 to 2008).
IE - infective endocarditis, mo - months, VL - viral load, AIE - active infective endocarditis, V - valves, IVDA - intravenous drug abuse, CHD - congenital heart disease, N/R - not recorded, 
Ao - aortic surgery, CPB - cardiopulmonary bypass,  Peric’l - pericardial surgery, CS  - coronary artery surgery,  * - actuarial.
Patient numbers for AIE, although noted separately, are included in the numbers given for IE.
 Surgery Markers IVDA Surgery Indication 30 day Complications Late Progression Survival
 With CPB    Endocarditis Mortality  Mortality to AIDS
Frater 1989 10 patients --- 9 V = 11 IE = 10 V = 1 N/R 4 N/A 5
 11 operations    AIE = 7   6-26 weeks  (12-30 months)
Aris 1993 39 patients --- 34 V = 38 IE = 33 V = 8 (20%) N/R 8 4 79% at
          1 year*
 1 partial CPB   CS = 1    (2 AIDS) (9-60 months) 48% at 
          5 years*
Everson Uip  30 patients --- N/R V = 8 N/R 2 (6.6%) “Same” 6 5 19/25 alive
1999     CS = 15   as uninfected (4 AIDS) (1-74 months) 13-74 months
    CHD = 5     (2 Peric’l)
    Peric’l = 2 
Mestres 2003 29 patients CD4 in 19 24 V = 26 AIE = 21 V = 7 (23%) 10 V = 9 3 65% at 1 year
 +2 off pump CD4  6-600  CS = 5  (5 AIE)    42% at 
 35 operations CD4 mean 289        3.4 years
Trachiotis  34 patients CD4 106-560 N/R V = 10 IE = 8 V = 1 (2.7%) 22 0 0 100%
2003  +3 off pump CD4 mean 360  CS =27 AIE = 6    Mean 2.4 years Mean 2.4 years
  VL higher in Vs 
Tec Chong  22 patients CD4 in 2 16 V = 22 IE = 20 V = 1 (4.5%) 3 (only serious  10 0 40% at 5 years
2003  N/R   AIE = 16  ones recorded)   20% at 8 years
Blyth 2006 49 patients CD4 in 42 0 V = 45 IE = 10  V = 3 (6%) 16 8 5 N/R
 50 operations CD4 37-1245  CS = 3 AIE = 6 (1 AIDS)  (3 AIDS)
  Average 685  Other = 2   
Filsoufi  2006 25 patients CD4 in 25 17 V = 15 IE = 14 V = 1 (4%) 9 3 N/R 92% at 
          1 year*
  CD4 51-1050  CS = 7 AIE = 4 (CD4 125)  (V = 1)  86% at 
          3 years*
  CD4 <500 in 17 Ao = 3       
Castillo 2008 37 patients CD4 in 39 24 V = 22 IE = 16 V = 2 (5%) 12 N/R N/R 91% at 1 year
 +2 off pump CD4 mean 490   CS = 12 AIE = 9 (1 AIE) 0 in isolated CS   81% at 5 years
  CD4 <500 in 22  Ao = 5      (estimated)
Boccara 2008 27 patients CD4 in 27 0 CS = 27  0 18 2 N/R 92% at 41 mo
  CD4 mean 502
  VL <50 in 25
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CD4 counts of 300 cells/microL as entry to surgery were 
suggested.(8) Flum et al. (1997) for the fi rst time reported on 
2 cases – their 4 cases being coronary surgery cases - receiving 
antiretroviral therapy in the form of zidovudine, prior to cardiac 
surgery.(11)
Aris et al.,(10) in 1993, in the biggest series to date, of 40 patients 
(1 with partial CPB), set out specifi cally to determine if CPB has 
an accelerating effect on progression of HIV disease (Table 1), 
and found progression of disease was similar in an HIV group 
not having cardiac operations. CPB did not appear to hasten 
progression to AIDS. Similarly Everson Uip et al.(12) (Table 1), in 
the fi rst paper from a developing country (1999), reporting on 
30 patients, came to the same conclusion. They saw no increase 
in postoperative complications in HIV patients.
Mestres et al.,(13) in 2003, following an initial report (Miro et al.,(14)) 
reviewed long-term outcome in 31 HIV patients, 24 being IVDAs, 
in their detailed paper. Mortality related to AIE was 23.4% 
(Table 1). Impairment of immunity was not seen. Importantly, 
they would now accept all referrals for surgery, irrespective of 
staging, unless there was some medical or surgical contra-
indication. 
The retrospective report by Trachiotis et al.(15)  [refer to CABG 
below] is different in that, 28 of the 37 patients were on Protease 
Inhibitors, pre- and post-operative CD4 cell counts were analysed 
and they looked specifi cally as to whether HIV patients were at 
greater risk due to immune depression, whether surgery increased 
progression to AIDS, whether the benefi t of surgery was dimi-
nished by the disease, and whether the team was at real risk for 
acquiring infection (Table 1). Six of 10 valve patients, CD4 
counts 106-480 cells/microL, were receiving Protease Inhibitors 
(PI). With 1 death and 7 complications, pre-and post-operative 
CD4 counts were not signifi cantly different. Opportunistic infect-
ions (OI) did not occur during a mean follow up of 2.4 years. 
They found favourable answers to their questions. Benefi t of 
surgery was clear. The signifi cant increase seen in cholesterol 
levels after commencing PI, was a cause for concern.  
Tec Chong et al.(16) (2003) in a 10 year  retrospective series, with 
16 of 22 patients undergoing valve replacements being IVDA, 16 
with AIE, encountered 3 major complications and 1 death soon 
after discharge. Seven had died by 1.2 years. (All the IVDA were 
dead by 8 years) (Table 1). HIV patients with IE would have 
good early outcome; recurrence of IE related to continued 
IVDA (as in 5), rather than a compromised immune system. 
Progression of disease was not reported, and ART not used.
Blyth et al.(17) (2006) reviewed 49 patients undergoing mainly valve 
surgery between May 1995 and April 2003, in the fi rst cardiac 
surgical paper from Africa (Table 1). These patients differed from 
those in other reports in that IVDA was not encountered, IE was 
uncommon and most patients were female. Early mortality was 
6% for 50 procedures, with a complication rate of 34.7%. CD4 
cell counts taken in 43 (range 37–1245 cells/microL) were not all 
available, as for emergencies, pre-operatively. Seemingly, active 
infective endocarditis in the markedly compromised, but small 
number (6) having emergency surgery, would lead to poor 
outcome: 4 of 6 emergencies for AIE, all 6 showing features of 
AIE at surgery, similar to Frater’s experience, died. Three patients, 
all undergoing emergency valve surgery for AIE, had CD4 counts 
of < 250 cells/microL: 2 with counts of 37 and 204 died at 10 
days and 3 months respectively, the latter with suspected endo-
carditis, whilst the third, with only one available count of 81 at 
1 month died at 3 months, the cause not being determined. 
The overall outcome in this series (41 leaving hospital in NYHA 
Class 1) was similar to that in the uninfected. No patient received 
ARV therapy. Cardiopulmonary bypass could not be said to 
hasten progression of disease.
Filsoufi  et al.(18) (2006) reported on 25 patients, 17 IVDA, and 13 
receiving anti-retroviral/s (ARVs) (Table 1). Of 15 valve replace-
ments, 1 (CD4 cell count 125 cells/microL, not on ARV’s) died, 
with complications (9) occurring in 5 valve patients with pro-
nounced risk factors. With 1 late valve death  - a patient with 
AIDS on HAART – 3 year survival  was >80% overall, “no signifi -
cant differences” being found in comparing results in a similar 
uninfected cohort. Outcome of CABG was excellent. They 
concluded that surgery in patients with AIDS should be 
undertaken.   
HIV DISEASE AND SURGERY
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Castillo et al.(19) (2008), reviewed their experience with 39 patients 
(2 off-pump), 28 receiving HAART. CD4 cell counts were <500 
cells/microL in 22 patients (Table 1). One early death (fulminant 
AIE) and 12 complications occurred, being limited to “high risk” 
groups (8 aortic and valve surgery patients). Plotted survival at 5 
years was 81%. These very good results may be related to the use 
of ARV’s/HAART and the fact that fewer patients are apparently 
presenting with AIE – a diffi cult entity in its own right.(13,19) They 
considered it practical to offer HIV+ as well as AIDS patients 
cardiac surgery with expectation of a good outcome, in view of 
the longer life expectancy related to ART usage.
CORONARY ARTERY SURGERY/CORONARY                   
ARTERY BYPASS GRAFTING
By 2006, only Everson Uip et al.(12) and Trachiotis et al.(14) had 
reported sizeable numbers of isolated coronary bypass graft 
operations. Usually CABG, in small numbers, only formed a part 
of reports. 
Yee(3) in 1991 had fi rst reported on 3 CABG in “AIDS patients”, 
1 combined with an aortic valve replacement. All came through 
surgery well, but 2 developed OI, 1 dying. Two were well at 9 and 
12 months. Flum et al’s.(11) 4 patients, reported 1997, with CD4 
counts >350 cells/microL , came through surgery well, but showed 
a reduction in CD4 cell counts, and progression of disease, 2 
developing AIDS, during follow up of 7–49 months. (Table 2) 
Everson Uip(12) (1999) had excellent results: 10 of 12 CABG 
were asymptomatic at follow-ups extending from 16 to 74 
months; 1 had AIDS at 24 months.  Mestres et al.(13) in 2003 
reported on 5 CABG, 4 with mean CD4 cell counts of 142 cells/
microL (3 <200), all receiving ARVs, with excellent outcome 
but noting the abnormal lipid profi les, expected an increased 
surgical need for CABG due to ARV’s.
Occasional case reports of CABG in patients with AIDS on and 
off-pump, on PI showed good results, but alluded to the expectation 
of increased premature coronary artery disease with increase in 
age and use of PI.(13, 20-23)     
Trachiotis et al.(15) (2003) reported on 27 isolated CABGs, 3 off-
pump; the largest detailed series which also included 10 valve 
procedures, 2 with CABG. Thirty–three percent of the CABG 
versus 40% of the valve patients had displayed AIDS-defi ning 
features, the latter having statistically higher mean viral loads (VL). 
Twenty-three CABG patients were on protease inhibitors (PI). 
Young males predominated. One valve surgery patient died 
peri-operatively. No late deaths occurred during a mean follow-
up of 2,4 years and no patient progressed to AIDS. Complica-
tions were mainly infective; infective complications were thought 
to be more common than in the uninfected (HIV-). Noting the 
apparent PI related signifi cant increase in cholesterol levels, they 
expect an increase in coronary artery disease (CAD) that will 
require surgery. This report clearly showed the excellent outcome 
that can be achieved in carefully chosen patients adherent to 
ARV’s and stable. While noting that the questions posed were 
favourably answered, they stressed the need for managing the 
side effects of PI therapy on lipid profi les.
Totally endoscopic CABG on an HIV patient has been reported.(24)
In the fi rst but small case-controlled study Jimenez-Exposito and 
others(25) (2006) compared 7 isolated HIV+ CABGs with 21 
TABLE 2: Conclusions from 4 small series which included AIDS cases
IVDA - intravenous drug abuse, AIE - acute infective endocarditis, IE - infective endocarditis, V - Valve surgery, CS - Coronary artery surgery
Name          Date     Surgery IVDA  AIE Early Death CPB worsens outcome?
Sousa Uva 1992(7) 10-9 V  3AIE, 3AIDS 1 No fi rm conclusions
Lemma     1992(8)       6 V            6          6 IE, 2AIE             1                 No signifi cant change in CD4
Brau 1992(9)       4V             4        2AIE, 1AIDS           0               No adverse effect on HIV
Flum          1997(11)      4CS           -                -                        0                Signifi cant CD4 count fall seen
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matched HIV- controls retrospectively. Mean pre-operative CD4 
count was 340 cells/microL. Four of the six patients receiving 
ARVs were also receiving protease inhibitors. Disease progres-
sion was not seen, no patient needing further CS at a mean 30,1 
month follow up. Sample size of HIV-infected patients was small 
and of younger age (Table 3). End points were lacking. 
Boccara and colleagues(26) (2008) in a well-balanced multi-centre 
case-controlled study (FRISCA-2) matched 27 HIV+ patients 
against 54 HIV- patients undergoing CABG in the setting of acute 
coronary syndrome (ACS) (Tables 1 and 3). They aimed at 
determining the eventual prognosis in these patients. Of the 26 
(96%) of the HIV+ patients on ARVs, 22 were receiving PI. 
Numbers of grafts were similar. At a 41 month median follow-up 
both major adverse coronary events (MACE) and the need for 
revascularisation by percutaneous intervention (PCI) were in-
creased in the HIV group. PCI was required only on native 
vessels. They concluded CABG to be safe and feasible.  A small  but 
signifi cant fall in absolute CD4 cell counts was seen, but compli-
cations and OI were not seen. They concluded that atheroscle-
rosis associated CAD was accelerated in these young HIV patients 
and advocated appropriate medication and aggressive lifestyle 
management. Lipodystrophy syndrome was present in 19. (Table3).
PERICARDIAL SURGERY                                                  
Pericarditis is well recognised to occur in HIV+ patients, and 
pericardial effusions in the pre-HAART era were frequently seen 
late in the disease.(27) Early in the HIV disease history, 1990, an 
increase in the incidence of pericardial effusions coincident with 
a rise in HIV was noted in Tanzania.(28) A review article(29) (2000) 
would say pericardial effusions could be “a marker for end stage 
disease” as CD4 counts tend to be low, OI and malignancy 
(e.g. lymphoma) being more frequently responsible for effusions, 
which themselves rarely cause death. These patients in recent 
experience seldom present to surgeons, unless there is a con-
comitant bacterial infection, causing a septic pericarditis needing 
formal drainage. Constrictive pericarditis so commonly caused by 
tuberculosis in South Africa and despite the close association 
between tuberculosis and HIV, was not referred for surgery in 
the HIV+ patient (personal experience).  Possibly these patients 
die before manifestation of constriction. Mayosi et al.(30) recently 
found in a multicentre study from Africa, and this lacked concrete 
diagnostic evidence, that “clinically evident HIV infection had a 
major impact on the death rate in patients” presumed to have 
tuberculous pericarditis (in line with the author’s suspicion). 
However, pericardiotomy for recurrent effusion, some with AFB 
positive fl uid cultures, and pericardiectomy for constriction 
(one calcifi ed) have been reported, but in small numbers.(28,31) Flum 
et al. (1995, 1997) considered surgical biopsy and drainage of 
the pericardium in patients with AIDS to have “minimal thera-
peutic effect” and were of little diagnostic benefi t.(11,32) Peri-
carditis has been less frequently seen with usage of HAART.(33) 
PAEDIATRIC CARDIAC SURGERY AND HIV                 
Mother to child transmission of HIV infection appears to have a 
trimodal expression, 15% having a rapidly progressive disease.(34) 
Estimates from a pooled study from Africa suggested 35% of 
infected infants might not survive 1 year.(35) The virus itself does 
not appear to be teratogenic.
“Literature regarding cardiac surgery in pediatric patients is non-
existent”.(36) Everson Uip’s series(12) listed 5 congenital heart 
HIV DISEASE AND SURGERY
TABLE 3: Case Control Studies in CABG
* - HIV+,  PI - Protease inhibitor, Progr - Progression to AIDS, MACE - Major Adverse Coronary Event, PCI - Percutaneous Coronary Intervention.
 HIV +*  Control       PI              Mortality        Complications      Progr.    MACE    PCI
Jimenez-    7 vs 21              4                  0*            57%  in         0           N/R         0*
Exposito                               6 on ARV      1 control     both gps 
Boccara    27 vs 54             22               0*                66%*          0          41%*     35%*
                                            26 on ARV        0                  68%                         18%       11%
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operations, but no details, other than 1 death at 4 months, the 
others being “asymptomatic” from 32 - 57 months. Theodore and 
colleagues(36) reported on total correction of Fallot’s Tetralogy in 
a 4 year old who post surgery sustained an extradural haema-
toma with neurological features but recovered fully. CD4 cell 
counts and CD4/CD8 ratios at 3 months mirrored pre-operative 
counts. This surgery is performed in South Africa, but has not 
been reported.
The WHO in November 2008 advised that all infants (children 
<12 months) suspected of or exposed to HIV should be tested 
at 4-6 weeks and, if positive, be treated with ARV for the rest 
of their lives.(37) This should bring cases to the surgeon’s door!
TRANSPLANTATION                                                      
The main concerns about heart transplantation in infected reci-
pients have been (1) HIV infection is a chronic, progressive sys-
temic disease, (2) that major drug interreactions between ARVs 
and immunosuppressants would occur and (3) that further de-
pression by immune suppressants would result.(38) Stock and 
Roland(39) regarded the last concern as “a fi nal major barrier to 
transplantation”. Interestingly, some immune suppressants such 
as cyclosporine, also suppress the virus.
Discussion and reports have hinged mainly around kidney and liver 
transplantation, with only a few reports on heart transplantation; 
a computer search has yielded little information.
Tzakis et al.(40) in 1990 reported on 25 transplants that included 
liver, kidney and 5 heart transplants. HIV infection was either present 
or incurred at surgery (blood transfusion). Four of the 5 heart 
transplants were alive at mean follow up of 2,75 years. Paediatric 
patients had a better outcome with 1 of 10 dying of AIDS as 
opposed to 5 of 15 adults in that series. In 1990 the death, from 
AIDS, was reported of the fi rst heart transplant in Italy, 6 years 
after transplantation, infection being established at surgery.(41) 
Calabrese et al.(42) in 2003 carried out heart transplantation in a 
man, diagnosed 4 years previously with AIDS (CD4 cell count = 20 
cells/microL). He had received treatment for metastatic Kaposi’s 
sarcoma, but infection was stable on ART with added PI, with a 
CD4 count of 250 cells/microL and undetectable VL, but he had 
developed a cardiomyopathy. Two years after transplantation 
clinical and cardiac status were good, but he had experienced 
6 episodes of rejection. He was in fact, one of the authors of 
the paper!
Halpern et al.(43) as far back as 2002, in considering ethical argu-
ments, HIV transmission and “burden of proof ”, felt it time to 
“remove barriers to transplantation” and not wait for “evidence 
of effi cacy to emerge”.  Bisleri and colleagues(44) (2003), reporting 
on a selected patient with good outcome at 2 years, proposed 
that heart transplantation should be reserved for those with 
CD4 counts in normal range, an undetectable VL and absence of 
past OIs.
In 2004 Pelletier and colleagues,(45) in reviewing transplantation in 
the HAART era and noting the reluctance to include HIV+ 
recipients, pointed out that many patients were accepted, parti-
cularly for liver transplantation, from groups known to have poor 
prognosis. From the (American) Scientifi c Registry for Transplant 
Recipients* they found only 20 patients undergoing heart trans-
plantation between January 1999  and July 2004 (Table 4*).
Uriel et al.(46) discussed 7 patients, 5 HIV+ prior to heart trans-
plantation, and 2 found to be HIV+ 1 and 7 years after trans-
plantation. CD4 counts were all above 300 cells/microL. No 
complications and no OIs occurred during intermediate follow 
up. HAART was administered to 6 of these patients. (2009)
Of note is that last year, in South Africa, 2 kidneys from an HIV+ 
donor were transplanted into 2 HIV+ recipients with good 
immediate outcome. The American state of Illinois, the fi rst state 
TABLE 4: Heart transplantation in HIV- versus HIV+ Cases 1994 – 2004 : 
SRTR Database; Pelletier et al.
Survival at 4 years in HIV+  recipients fell to 40%, but numbers were small. 
Graft Survival
 1 year  3 year
Recipient Survival
 1 year  3 year
HIV  -  Cases   9154 85.2%      78.4% 85.6% 79%
HIV  +  Cases     20 90%          60% 90% 90%
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to do so, has legalised organ donation/receipt between HIV+ 
persons. In an information document, a large American medical 
aid equivalent, Blue Cross and Blue Shield of Massachusetts, 
Inc,(47) in a 2007-2008 update would extrapolate guidelines for 
kidney transplantation to any other organ, as set out by the 
British HIV Association and the British Transplantation Society 
Standards Committee. Patients with life expectancy of at least 5 
years, with CD4 counts >200 cells/microL, undetectable VL, 
adherence to HAART, all for at least 6 months, as well no AIDS-
defi nining illness after “successful immune reconstitution after 
HAART”, would be suitable recipients.(46)
Guidelines set out by the Netherlands Society of Cardiology and 
Netherlands Assciation for Cardiothoracic Surgery consider HIV 
to be an active systemic infection, which would be a defi nite 
contraindication. Recognising availability of more information, but 
no long term follow up, they are doubtful about suitability in 
view of increasing donor shortages.(38) 
Stock and Roland,(48) noting more frequent rejection episodes 
and the prolonged depression of CD4 cell counts after treat-
ment for these, refer to improved and comparable results in 
solid organ transplantation in selected patients since initiation of 
HAART; rejection episodes are probably due to a dysregulated 
immune system.
Numerous issues, not the least being availability of organs and the 
unsatisfactory outcome prior to HAART, have delayed general 
acceptance of the HIV+ patient for transplantation. With the 
advances in ARV’s, the expertise available in immunology and 
ARV and HIV management, it is likely that heart transplantation in 
HIV patients is not far from acceptance.
Cardiac transplantation in the HIV situation is under discussion in 
South Africa(49) where again, the advent of ARV/HAART was 
markedly delayed, and the Public Health System has failed.      
SOME ASPECTS OF VASCULAR DISEASE  AND           
ARV/HAART 
Vascular
Joshi et al.(50) described a particular histological arteriopathy in 
blood vessels of children with HIV, one having aneurysms of the 
right coronary artery with myocardial infarction. Bayley(51) in 1990 
reported peripheral gangrene, implying proximal arterial occlu-
sion, requiring high amputation, in young HIV+ patients, in 
Zambia, while unusual multiple aneurysms of the aortic arch, 
brachiocephalic and subclavian arteries were encountered in 
Zimbabwe.(52) Nair et al.(53,54) (1997, 2000) encountered these 
entities locally: they felt that the histological similarities in the 2 
conditions would have “a common pathogenetic event”. In the 
absence of micro-organisms and atherosclerosis, it was suggested 
that the virus might directly involve the vessel.(54) Premature 
coronary artery disease has been noted in young HIV patients.(55,56) 
Tabib et al.(57) found distinctive histological features which they 
regarded as indicative of an accelerated process of coronary 
artery atherosclerosis in young HIV+ patients.
Endothelial dysfunction has been noted in HIV disease, as has 
hypertriglyceridaemia, hypercoagulability and coronary artery 
disease, even before the use of protease inhibitors.(58)  Kamin and 
Grinspoon(59) in an editorial review in 2005 concluded that mole-
cular and clinical studies would support the occurrence of  vascular 
disease and endothelial dysfunction in HIV + individuals. In a study 
on porcine coronary arteries,(55) Tat protein which is an HIV 
regulatory protein was shown to interfere with endothelial 
relaxation in porcine arteries. This endothelial dysfunction may 
well relate to vascular disease. 
The virus itself can enter the vessel wall and perhaps directly cause 
specifi c disease of the vessel wall: Scholtz(60) refers to a presenta-
tion in which Tudhope reported a high viral load in the arterial 
wall of an HIV+ patient whilst  Barbaro et al.(61) found evidence 
of the virus in the coronary artery wall in a fatal case of myo-
cardial infarction in a patient with HIV-associated coronary 
arteritis. Johnson et al.(62) from a literature review in 2003 con-
cluded these patients may be predisposed to develop vasculitic 
HIV DISEASE AND SURGERY
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syndromes. Recently in a complex study in coronary artery tissue, 
Eugenin et al.(63) showed that the virus could enter smooth 
muscle cells (SMC), both in vitro and in vivo. Further in vitro 
work showed infected SMC would release a chemokine known 
to be a “critical mediator of atherosclerosis” - so the virus may 
possibly be involved in a tortuous pathway which would “explain 
the atherosclerosis and vasculopathy” seen in HIV disease. 
Interestingly, by looking at soluble endothelial and platelet activa-
tion markers in 3 matched HIV+ cohorts,  (1) on protease inhi-
bitors (PI), (2) on NNRTI (3) and treatment naïve patients, 
Francisci et al.(64) concluded that, in the short term at least, 
chronic HIV disease was responsible for changes in these markers 
of endothelial function, rather than ARV therapy. In contrast, Stein 
et al.,(65) by measuring fl ow mediated vasodilation in brachial 
arteries and measuring lipoproteins in PI treated versus treatment 
naïve patients, concluded that the “atherogenic lipoprotein 
changes” noted and endothelial dysfunction were attributable to 
protease inhibitors.
ARV AND HAART                                                           
In 1998, Palella and colleagues(66) reported on the dramatic fall 
in mortality and morbidity documented in the markedly com-
promised HIV+ patients as intensity of combination therapy, 
especially with the addition of protease inhibitors (PI), was 
increased. The Cascade collaboration(67) study supported these 
fi ndings when comparing treatment before and after the intro-
duction of HAART. 
Also in 1998, Henry et al.(68) published a research letter, based 
on fi ndings in 2 young men which led to a review of patients 
receiving PI, illustrating “premature coronary artery disease 
(CAD) with protease inhibitors”. Carr et al.(69) described the 
syndrome of lipodystrophy, hyperlipidaemia and insulin resistance 
as seen in patients receiving PI therapy, whilst Periard and col-
leagues(70) demonstrated increased total cholesterol and tri-
glyceride levels – “atherogenic dyslipidaemia” - in PI recipients. 
There appeared to be a distinct and disturbing dark side to pro-
tease inhibitors. 
Duration of treatment was seen to have a direct bearing on 
the incidence of myocardial infarction, especially in men on PI for 
longer than 18 months.(71) The DAD study (2003)(72) showed a 
duration- related, relative rate increase in myocardial infarction; 
the absolute risk was low. Currier and colleagues(56) in a very 
large study determined the signifi cantly increased risk in the 
young age group 18 to 33 years on ARV for developing coro-
nary artery disease. In a follow on from their earlier observa-
tion, the DAD study group(72) confi rmed that duration of PI 
usage related to myocardial infarction. In a smaller group on 
NNRTI this was not evident.
Triant et al.(74) in a study involving 3851 HIV patients and more 
than 1 million  HIV-uninfected, found, in brief, a signifi cant increase 
in acute myocardial infarction rates in the HIV patients on ARV.
Acute type B lactic acidosis, a well-recognised complication of 
NRTIs, has been reported after aortic root replacement in a 
patient on HAART.(75) 
CARDIAC SURGERY IN SOME TRAINING UNITS        
IN SOUTH AFRICA
In answer to a simple questionnaire given to 4 units, information 
from a website and personal discussion, it is apparent that 5 units 
are operating on HIV+ patients, and with the exception of 1 unit , 
all cardiac surgeons were operating on these patients.  Entry 
criteria were used by all, but differed; they were not always 
exactly defi ned, but all were based on CD4+ cell counts, general 
status and well-being of the patient, with use of ARVs playing a 
role.  Two units did not routinely test all patients for HIV disease.
Thus, broadly:
CD4 cell counts, Clinical status and Elective Surgery (4units)
Unit 1:  Patients with CD4 cell counts > 400 cells/microL were 
accepted, those with counts 200 – 400 were individual-
ised with regard to absence of AIDS defi ning conditions 
and nature of surgery. Usually would refer those with CD4 
cell counts < 200 cells/microL for ART. Would prefer all 
patients to be on ARV’s.
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Unit 2:    Those with low CD4 counts (< 200 cells/microL ) ac-
cepted but to be on ARVs.* 
Unit 3:    Patients with CD4 counts >200 cells/microL accepted 
for elective surgery* Those with counts <200 cells/
microL, but otherwise well, referred for ARVs with aim 
to get CD4 count >200 cells/microL.
Unit 4:    In view of a large past experience and review, patients 
with CD4 counts >200 cells/microL (previously >400) 
and without any stigmata of AIDS, are accepted. Patients 
on ARVs for more than 3 months, irrespective of CD4 
count, otherwise well (no OI), accepted. Viral load (VL) 
would be considered. 
Emergency surgery (5 units)
Emergency referrals for surgery would be accepted without 
CD4 estimation, or even HIV testing (by some), but would need 
to be free of AIDS-defi ning conditions and would need to fulfi l 
general criteria for emergency surgery, as in uninfected patients. 
Children (1 unit – all units not questioned)
Children younger than 18 months with CD4 to total lymphocyte 
(CD4/TLC) percentage  >20%, or receiving ARVs for longer than 
3 months and children older than 18 months with a CD4/TLC 
percentage >15%, or on ARV’s for longer than 3 months would 
have surgery.
*Advanced AIDS would exclude patients
SOME  ANSWERS                                                             
From this brief review of cardiac surgery (and vascular surgery) in 
HIV+ patients many answers are apparent. The initial one con-
cerning further depression of the immune system by cardiac surgery 
and CPB was clear some years ago: depression caused is tran-
sient(5,6) and even those patients with advanced disease tolerate 
surgery well.(2,4,7-9,13,17,20,23)
HIV disease is recognised as a chronic disease and even without 
ARV therapy, life expectancy from time of seroconversion is at 
least 10 years. Acceleration of disease progression in relation to 
cardiac surgery has not been shown. With advances in ARV 
therapy and expert care, and those are certainly available in 
South Africa, good life expectancy can be further extended.(1) 
The expected high peri-operative mortality and morbidity rates 
have not consistently occurred, and results are very similar to 
those in the uninfected.(12,17) Even Frater’s initial early experiences 
in sick IVDA with AIE (some possibly with AIDS) not responding 
to appropriate antibiotic therapy, and especially Yee operating on 
what he called “AIDS patients”, showed these patients could get 
through surgery.(2,4)  OI in Yee’s patients could not be blamed on 
surgery or CPB. Certainly the type of patient and the nature, 
stage and severity of the illness, as in all surgery, would have 
bearing on outcome. More recent experience with AIE in IVDA 
does not refl ect results of the fi rst reports.(16) AIE is more likely in 
IVDA than other HIV patients, with left sided valves most 
commonly requiring surgery.(2,16,19) Our experience was, in the 
absence of IVDA, that IE and AIE were not common, and 
when seen occurred more commonly in patients with low 
CD4 counts, left-sided valves being affected; these patients did 
not fare well.(17) Reportedly, IE in IVDA more commonly affects 
the tricuspid valve, and generally has a good outcome, while 
left-sided IE runs a worse course and mortalities of 5-15% 
could follow surgery. HIV+ IVDAs with CD4 cell counts <200 
cells/microL, suffered signifi cantly increased mortality.(14) This 
perhaps explains Frater’s  early experience.(2) IE in IVDA is now 
less frequently seen.(13,18) Recurrent IE in IVDA relates to a return 
to drugs rather than immune compromise.(2,13,16)   
Based on limited available reports, CABG has better results than 
valve surgery(18,19) and can be done less invasively. More cases 
are being referred, possibly due to PI usage and disturbed lipid 
profi les.(13)
Concern about surgical injury to the surgeon is real, but no record 
of a member of a surgical team having become infected after injury 
has been found. Techniques to avoid injury are well described; 
post exposure prophylaxis (PEP) must be available (although not 
pleasant!). Personal observation would indicate that there is still 
reluctance in some to operate on these patients. 
Acceptance for surgery has changed, so that some will now 
accept all patients, provided they do not have some other 
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medical or surgical contra-indication to surgery; this will include 
patients not on ARV’s.(13)  Some would want ARV usage to reduce 
VL, patients to be in a stable state and would seemingly accept 
patients with AIDS.(15,18,19)  The very good results emerging in the 
immediate and medium term in the HAART era (post-1996) 
would support this. Surgery in the carefully assessed patient with 
AIDS, not on treatment, in the absence of OI and standard contra-
indications for surgery would now seem practical, immune 
reconstitution and initiation of ARV therapy being born in mind.
Reports on cardiac surgery in patients receiving ARV/HAART 
are few. The use of ARV’s and especially HAART has altered this 
disease remarkably: not only has expected lifespan of the infected 
been improved but once immune reconstitution has taken place, 
OI are, at least, reduced and quality of life improved.(65,66) This 
has an impact on surgery.(15,19)
Drug side effects and effects of the disease itself, as discussed, on 
available evidence, do alter the lipid profi le and lead to vascular and 
particularly coronary artery disease. This would require monitoring 
of lipids and careful use of cholesterol lowering medication as well 
as indicators of infl ammation – an aspect beyond this paper.
There has been little discussion about type of valve to be used. 
Some have used from homografts to mechanical valves,(10,13) 
others favoured mechanical valves.(16,17) It seems reasonable to 
follow the protocol used in the uninfected of bioprosthetic valves 
in the older population (>65 years), and mechanical valves in 
those younger, knowing the early deterioration of bioprosthetic 
valves in young patients.(17)  Homografts would have a role to play 
in IE involving the aortic root. 
The use of prognosticators such as CD4 cell counts and VL are 
essential in HIV disease management: CD4 cell counts contribute 
to staging of disease, whilst VL in those on ARVs refl ects success 
of viral suppression. This author strongly advises informed HIV 
testing for all potential cardiac/vascular surgery patients, especially 
where the result will infl uence management and subsequent 
outcome.  
The earlier use of ARVs, where waiting lists are the order of the 
day, has been suggested(17) to allow for stability and improvement 
in cases with low CD4 cell counts. In South Africa, according to 
current national guidelines (under revision) ARV’s are only advised 
once CD4 count is <200 cells/microL, or in case of an AIDS-
defi ning illness. Most infectious diseases specialists in South Africa 
would start potential elective cardiac/vascular surgery patients on 
ARV’s with CD4 counts <350 cells/microL. Mortality is neverthe-
less greater in these patients than in the uninfected.(1)
 
Tragically, most of the South African HIV community was denied 
anti-retroviral treatment for many years…
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